$JAZZ News

Jazz Pharmaceuticals (JAZZ) Q2 Earnings: What To Expect

Will Jazz (JAZZ) Beat Estimates Again in Its Next Earnings Report?

Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026

Needham Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $282

Jazz Pharmaceuticals (JAZZ) Stock Still Looks Like A Bargain After A 119% Run

Jazz Pharmaceuticals (JAZZ) Refocuses Its Sleep Franchise, Is The Stock Still Cheap?

Canaccord Genuity Initiates Coverage On Jazz Pharmaceuticals with Buy Rating, Announces Price Target of $290

Wells Fargo Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $285

Barclays Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $260

Deutsche Bank Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $270

Truist Securities Maintains Buy on Jazz Pharmaceuticals, Lowers Price Target to $254

Jazz Pharmaceuticals Investors Eye Ziihera Launch in GEA as Key Driver, UBS Says

Is HRMY Stock Worth Buying With Neutral Signals and Cheap Valuation?

Jazz Pharmaceuticals (JAZZ) Stock Gets Fair Value Boost As Ziihera Views Split Analysts

Jazz Pharmaceuticals (JAZZ) Expands AbCellera Tie Up As Zepzelca Trial Misses Goal

Jazz Pharmaceuticals and AbCellera Biologics Inc. (ABCL) Announce Collaboration

JAZZ & ABCL Team Up to Develop Next-Generation Solid Tumor Therapies

Jazz and AbCellera sign deal for T-cell engagers in solid tumours

Jazz Pharmaceuticals and AbCellera Partner on Antibody Programs for Solid Tumors

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies